Dr. Gradishar on the Role of Neratinib in the Treatment of HER2+ Breast Cancer

William J. Gradishar, MD
Published: Friday, Oct 13, 2017



William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the role of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

In the early stage, one of the challenges is integrating pertuzumab (Perjeta) and neratinib (Nerlynx) into the neoadjuvant setting.

Neratinib may be considered in high-risk patients after treatment with the combination of pertuzumab and trastuzumab (Herceptin).
 
SELECTED
LANGUAGE


William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the role of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

In the early stage, one of the challenges is integrating pertuzumab (Perjeta) and neratinib (Nerlynx) into the neoadjuvant setting.

Neratinib may be considered in high-risk patients after treatment with the combination of pertuzumab and trastuzumab (Herceptin).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x